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Repurposing Mebendazole as a Replacement for Vincristine
for the Treatment of Brain Tumors
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The microtubule inhibitor vincristine is currently used to treat a variety of brain tumors, including low-grade glioma and anaplastic
oligodendroglioma. Vincristine, however, does not penetrate well into brain tumor tissue, and moreover, it displays dose-limiting
toxicities, including peripheral neuropathy. Mebendazole, a Food and Drug Administration–approved anthelmintic drug with a
favorable safety profile, has recently been shown to display strong therapeutic efficacy in animal models of both glioma and
medulloblastoma. Importantly, appropriate formulations of mebendazole yield therapeutically effective concentrations in the
brain. Mebendazole has been shown to inhibit microtubule formation, but it is not known whether its potency against tumor cells
is mediated by this inhibitory effect. To investigate this, we examined the effects of mebendazole on GL261 glioblastoma cell
viability, microtubule polymerization and metaphase arrest, and found that the effective concentrations to inhibit these functions
are very similar. In addition, using mebendazole as a seed for the National Cancer Institute (NCI) COMPARE program revealed
that the top-scoring drugs were highly enriched in microtubule-targeting drugs. Taken together, these results indicate that the
cell toxicity of mebendazole is indeed caused by inhibiting microtubule formation. We also compared the therapeutic efficacy
of mebendazole and vincristine against GL261 orthotopic tumors. We found that mebendazole showed a significant increase
in animal survival time, whereas vincristine, even at a dose close to its maximum tolerated dose, failed to show any efficacy. In
conclusion, our results strongly support the clinical use of mebendazole as a replacement for vincristine for the treatment of brain
tumors.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2017.00011

INTRODUCTION
The microtubule polymerization inhibitor vincristine has a broad spectrum of use
in cancer chemotherapy, for both hematological malignancies and solid tumors.
Vincristine is also used in the treatment of
a variety of central nervous system (CNS)

tumors. Along with procarbazine and
lomustine (CCNU), it constitutes the PCV
regimen, which is currently considered
standard of care for newly diagnosed
patients with 1p/19q co-deleted anaplastic
oligodendroglioma (1,2) and adult patients
with low-grade glioma (3).
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Because of its large size (MW 825 daltons) and its susceptibility to transport
by Mrp1 and Pgp, vincristine has poor
blood-brain barrier (BBB) penetrance (4,5).
Therefore, its use for the treatment of CNS
tumors has been questioned (4,6). Vincristine also has significant dose-limiting toxicities. The peripheral neuropathies resulting
from its use can be debilitating and permanent, often halting use of the drug (7,8).
Mebendazole, an anthelmintic with a
rather benign side effect profile that has
been in longstanding clinical use, has recently been shown to display significant
therapeutic efficacy in animal models of
both glioblastoma and medulloblastoma
(9,10). Depending on crystallization conditions, mebendazole can form three
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different polymorphs, termed A, B and C,
which display significant differences in
bioavailability (11,12). As a result, the
distinct polymorphs, when administered orally, also have different toxicity
and therapeutic effects, as both anthelmintic and anticancer agents (11,12).
However, once dissolved, the respective
polymorphs have identical properties.
Both polymorphs B and C have good
bioavailability and BBB penetration and
display similar therapeutic efficacy in
the GL261-C57BL/6 glioblastoma model,
whereas polymorph A totally lacks in
efficacy (12).
Mebendazole has been shown to
inhibit microtubule formation (9,13),
but it is not known whether its tumor
cell–killing effect is solely mediated by
its microtubule destabilizing effect. Indeed, mebendazole has been shown to
inhibit a number of protein kinases (14).
In this study, therefore, we examined
the mechanisms of tumor cell killing of
mebendazole in detail, motivated by
the possibility that mebendazole may
be able to serve as a safer and more effective replacement for vincristine for
the treatment of brain tumors. Thus,
we determined the inhibitory effects of
mebendazole on GL261 glioblastoma cell
viability, metaphase arrest and microtubule polymerization and compared these
effects with those of vincristine. We also
compared the therapeutic efficacies and
toxicities of mebendazole and vincristine
in the GL261-C57BL/6 syngeneic orthotopic mouse model.
MATERIALS AND METHODS
Tissue Culture
The GL261 glioblastoma cell line was
maintained in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and antibiotics. All cells were maintained at 37°C
in humidified air containing 5% CO2.
Cytotoxicity Assay
GL261 cells were seeded in 96-well tissue culture plates at 3,000 cells per well.
After 24 h, cells were treated with a range

of concentrations of either mebendazole
or vincristine for 96 h, with a medium
change at 72 h. At 96 h, an MTT assay
(Sigma) was performed and cell viability
was determined by absorbance at
595 nm.
Tubulin Polymerization Assay
The tubulin polymerization assay was
performed essentially as described (15).
In brief, GL261 glioblastoma cells were
seeded at 3 × 105 cells per well in 6-well
tissue culture plates. The next day, cells
were treated with a range of concentrations of either mebendazole or vincristine for 24 h. Subsequently, the cells were
rinsed in PBS at 22°C and harvested at
the same temperature in hypotonic lysis
buffer (1 mM MgCl 2, 2 mM EGTA,
0.5% NP-40, 20 mM Tris HCl pH 6.8)
containing protease inhibitors and benzonase. The samples were centrifuged
at 13,000g for 10 min at 22°C to separate
polymerized (P) from soluble (S) tubulin.
The supernatant containing the depolymerized (S) tubulin was transferred to
a new tube. The pellet containing polymerized (P) tubulin was resuspended in an
equal amount of hypotonic lysis buffer.
Equal amounts of protein were loaded
on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
gels and analyzed by western blotting
with anti–α-tubulin and GAPDH antibodies using chemiluminescence (Amersham ECL Western Blotting System, GE
Healthcare). The blots were scanned
and quantified using ImageJ 1.44p
(National Institutes of Health). Microtubule polymerization was determined as
the percentage of polymerized tubulin
over total tubulin.
Immunofluorescence
GL261 cells were seeded at a density of
30,000 cells per well in 24-well plates containing coverslips coated with 0.1 mg/mL
high-molecular-weight polylysine (Sigma)
and subsequently with 0.5 μg/cm2 laminin from Engelbreth-Holm-Swarm
murine sarcoma (Sigma). The following day, cells were exposed to 6 Gy of
X-ray radiation. At designated time

points post-IR, cells were washed in
PBS and fixed in 4% formaldehyde in
PBS at room temperature. Once the
cells were fixed, immunofluorescence
was performed using an MPM2 antibody (Millipore) and counterstained
with DAPI. For each condition, a total
of 10 fluorescence micrograph images
were taken with a Zeiss Axiovert 200M
inverted microscope running on Axiovision software. For each image field,
the total number of cells and the number of MPM2-positive cells were quantified. The mitotic index was calculated
at each time point using the number of
MPM2-positive cells as a percentage of
the total number of cells counted in all
10 fields.
Luciferase Expression by Lentivirus
The pLenti-UBC-Gluc-T2A-Puro
lentiplasmid was purchased from
Targeting Systems. This plasmid was
transfected into 293NT cells, along with
plasmids carrying the virus reverse
transcriptase gene (REV), the envelope
glycoprotein gene (VSV-G) and the
polymerase gene (GAG-Pol), using Lipofectamine 2000 (Invitrogen). Virus was
harvested after 48 h and used to infect
GL261 cells to make GL261/GLuc.
Animal Experiments
Female C57BL/6 mice (age 3 months)
were purchased from Jackson Labs. The
transduced GL261/GLuc cells were used
for brain tumor implantation. Tumor
cells (20,000/2 μL) were implanted using
a stereotactic frame through a burr hole
drilled 2 mm lateral to the bregma and
1 mm posterior to the coronal suture at a
depth of 3 mm below the dura at a rate
of 1 μL/min.
Tail vein blood was collected daily and
used for Gaussia luciferase quantification by luminometry assay as previously
described (16). Gaussia luciferase substrate was purchased through Targeting
Systems. Mice were randomly assigned
to four different treatment groups once
their G-luciferase values exceeded 1.3.
Mebendazole was administered by oral
gavage. Vincristine was administered
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by intraperitoneal injection. Polymorph
C mebendazole tablets (S2017, Aurochem Laboratories Ltd.) were a gift
from G. Riggins, Johns Hopkins University School of Medicine. Tablets were
grounded into powder and resuspended
in a PBS/sesame oil (50% v/v) mixture
to achieve better gastrointestinal absorption of the drug. The gavage tip was
coated with agave syrup prior to administration. Mebendazole suspensions were
made fresh weekly.
Animals were observed daily for any
signs of deterioration, neurotoxicity,
movement disorders or signs of pain and
distress in accordance with our Institutional Animal Care and Use Committee
protocols, and euthanized when symptoms appeared.
Von Frey Filament Testing
Allodynia was determined essentially
as described (17). Briefly, the mouse
plantar surface of the hind paw was
probed with calibrated von Frey hairs,
with bending forces from 8 mg to 4 g.
The 50% withdrawal threshold (the force
of the von Frey hair, in grams, to which
the animal reacts in 50% of instances)
was determined by applying the hairs six
times. Time between measurements was
at least 30 s between alternating paws.
Comparison to baseline sensitivity was
used to determine significant decrease in
the withdrawal threshold.
Statistical Analysis
Direct comparisons were conducted
using unpaired two-tailed Student t test.
Statistical analysis was performed using
GraphPad Prism 6 Software. A P value
lower than 0.05 was considered significant. The Kaplan-Meier estimate and a
log-rank (Mantel-Cox) test were used to
generate survival curves with the GraphPad Prism 6.0 software.
RESULTS
Mebendazole and Vincristine Have
Similar Cellular Mechanisms of Action
To examine whether the cytotoxic effects of mebendazole are indeed caused

by its inhibitory effect on microtubule
formation, we compared the relative potencies of mebendazole and vincristine
on microtubule formation and cell viability in GL261 glioma cells. Microtubule
formation was quantified by hypotonic
lysis of cells, followed by separation of
polymerized and unpolymerized tubulin
in the pellet and supernatant fractions,
respectively (15). Cell viability was determined using the MTT assay.
From the data shown in Figure 1, we
determined that the half maximal effective concentration (EC50) of mebendazole
for microtubule depolymerization
(132 nM) is very similar to that for cell
viability (160 nM). A similar relationship
holds for vincristine, although the difference between the EC50 for microtubule
depolymerization (1.36 nM) and that for
cell viability (2 nM) is slightly larger.
As noted previously (15), the cellular microtubule polymerization assay

is subject to considerable variability.
Therefore, to further examine the
correlation between the effects of mebendazole on cytotoxicity microtubule
depolymerization, we also determined
the EC50 of both mebendazole and
vincristine to induce mitotic arrest, a
process that is critically dependent on
microtubule formation. To determine
the fraction of cells that are in the mitotic phase of the cell cycle, we used the
MPM2 monoclonal antibody that binds
to a phosphoamino acid–containing
epitope present on multiple proteins
during mitosis (18). Using this method,
we first determined the time dependence of mitotic cell accumulation using
a saturating concentration (500 nM)
of mebendazole. We found that upon
addition of mebendazole, the number
of mitotic cells steadily increased over
the first 8 h and reached a plateau by
24 h (Figure 2A). Next, using an incu-

Figure 1. Mebendazole and vincristine have similar inhibitory effects on cell viability and
microtubule polymerization. (A,B) Western blots illustrating microtubule depolymerization
caused by incubation of GL261 cells with the indicated concentrations of mebendazole
(MBZ) and vincristine (VCR). Cells were processed, and polymerized (P) and soluble (S)
tubulin were separated by centrifugation as described in Materials and Methods. (C,D)
Concentration dependence of microtubule polymerization and cell viability: (C) mebendazole, (D) vincristine. Microtubule polymerization was determined as the percentage
of polymerized tubulin over total tubulin. Determination of cell viability was performed as
described in Materials and Methods. Data shown were normalized to vehicle control values and represent the mean ± SEM of three and at least eight independent experiments
for the microtubule polymerization and cell viability experiments, respectively.
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Figure 3. Mebendazole, but not vincristine, promotes the survival of glioma-bearing
mice. Kaplan-Meier survival curves of mice implanted with GL261 glioma cells and
treated with different doses of mebendazole and vincristine. Group sizes of the respective groups are 11–12.

Figure 2. Mebendazole and vincristine
induce metaphase arrest with a similar
concentration dependence as that of
cell viability. (A) Time dependence of
mebendazole-induced metaphase arrest. Mebendazole concentration was
500 nM. Data shown represent the
mean ± SEM of three independent experiments. (B,C) Concentration dependence
of metaphase arrest: (B) mebendazole,
(C) vincristine. Data shown represent the
mean ± SEM of three independent
experiments.

bation time of 8 h, we determined the
respective EC50 values of mebendazole
and vincristine for mitotic arrest to be
192 nM and 2.49 nM (Figures 2B, C).
Remarkably, the ratio of the EC50 for mitotic arrest over the EC50 for cell viability
for mebendazole (1.20) is very similar
to that for vincristine (1.24). Thus, the

data obtained with this more accurate
method of probing cellular microtubule
function strongly support the hypothesis
that the cellular mechanisms of action of
mebendazole and vincristine are indeed
identical.
To further probe the mechanism of
action of mebendazole, we used the
COMPARE search tool of the NCI Developmental Therapeutics Program to
find drugs that have similar mechanisms
of toxicity in a set of 59 different human
tumor cell lines that cover 9 different
tissue types, including brain (19,20). Of
the 20 highest-scoring compounds with
known mechanisms of action, 70% have
been shown to modulate microtubule
dynamics, including vinblastine, taxol,
colchicine and lesser known drugs such
as rhizoxin, podophyllotoxin and maytansine. Thus, this analysis provides further evidence that the major mechanism
of action of mebendazole is microtubule
destabilization.
Mebendazole, but Not Vincristine,
Promotes the Survival of GliomaBearing Mice
With regard to therapeutic efficacy, it
is important to note that, depending on
crystallization conditions, mebendazole
can form three different polymorphs,
termed A, B and C, which display significant differences in solubility and

bioavailability (11,12). As a result, the
distinct polymorphs, when administered
orally, also have different toxicity and
therapeutic effects, as both anthelmintic
and anticancer agents (11,12). However,
once dissolved, the respective polymorphs have identical properties. As has
been shown recently, polymorphs B and
C display similar therapeutic efficacy in
the GL261-C57BL/6 model, with polymorph C being slightly more effective
than polymorph B, and polymorph A
totally lacking in efficacy (12). In this
study, therefore, for all in vivo experiments, we used polymorph C.
For the animal studies, we performed orthotopic implantation of
the GL261 cells in syngeneic C57BL/6
mice. To monitor tumor formation,
we first transduced GL261 cells with
Gaussia luciferase (Gluc), a secreted
luciferase that can be quantified using
a small volume of blood (16). Tail vein
blood was collected every 1–3 d, and
mice were randomized and treatments
started once Gluc levels reached a predetermined value that corresponded
to approximately 10 d after tumor cell
implantation, as determined from pilot
studies.
To determine the relative therapeutic
efficacies of mebendazole and vincristine
in mice, we used two doses for each drug.
In the literature, values for the maximum
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tolerated dose (MTD) of vincristine
for mice range from 1.17 to 1.5 mg/kg
(21–23). Therefore, we chose to examine
the effects of 0.5 and 1.0 mg/kg of vincristine. Dosing for mebendazole is less
extensively documented in the literature.
In one study, daily oral administration
of mebendazole at 50 mg/kg was shown
to be well tolerated, whereas a dose of
100 mg/kg showed apparent toxicity, as
indicated by weight loss (9). However, as
our pilot experiments did not reveal any
toxicity at the higher dose of 100 mg/kg,
we included both 50 mg/kg and 100 mg/kg
in this study.
The control group had a mean survival
of 10.1 d after treatment onset (95% confidence interval [CI], 9.2–11, Figure 3).
Weekly intraperitoneal administration
of vincristine at either 0.5 mg/kg (mean
survival of 11 d, 95% CI, 10.16–11.8)
or 1.0 mg/kg (mean survival of 11.9 d,
95% CI, 8.9–14.9) did not show a significant survival benefit. Daily oral
gavage of mebendazole, however, significantly enhanced animal survival with
both 50 mg/kg (mean survival of 17 d,
95% CI, 13.4–20.6) and 100 mg/kg (mean
survival of 19 d, 95% CI, 15.3–22.9).
Peripheral neuropathy is a major
side effect of vincristine and other microtubule drugs in the clinic. Thus, to
quantify drug toxicity, we also examined
the emergence of sensory allodynia by
measuring footpad sensitivity using von
Frey filaments. As paw withdrawal may
be modulated by the presence of brain
tumors, we performed an additional
study in non–tumor-bearing animals.
As expected, vincristine caused a significant increase in footpad sensitivity
(Figure 4A). Mebendazole caused a tendency toward increased footpad sensitivity, but this increase was not statistically
significant. We also examined the
toxicity of combined mebendazole and
vincristine. Combined administration
of both drugs caused rapid weight loss
after less than 1 wk (Figure 4B), triggering euthanasia of the animals. Combining mebendazole with vincristine
also appeared to further increase the
emergence of neuropathy. In contrast,

Figure 4. Drug-induced toxicities. (A) Peripheral neuropathy in mebendazole- and vincristinetreated mice. Shown are the mean ± SEM (n = 12) of footpad sensitivity measurements using
von Frey filaments on d 6 after treatment initiation. (B) Animal weights before and during
treatment. Data points represent the weight averages for each group ± SEM (n = 12).

administration of mebendazole or vincristine as monotherapy caused minor
weight loss over this time period.
DISCUSSION
Our in vitro analysis strongly indicates
that the mechanisms of cell killing by
mebendazole are identical to those of
vincristine. We also show that, whereas
mebendazole has a significant therapeutic effect in the GL261-C57BL/6 model,
vincristine has no efficacy at all in this
model.
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We have provided two independent
lines of evidence indicating that the
cytotoxicity of mebendazole is caused
by its inhibitory effect on microtubule
polymerization. First, the EC50 for mebendazole-induced cell toxicity is very
similar to that of microtubule depolymerization and metaphase arrest.
In addition, the same relationships between the EC50 values for mebendazole
for cell toxicity, microtubule depolymerization and metaphase arrest hold
for the effects of vincristine on these
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functions. Second, the NCI-DTP COMPARE analysis for cell toxicity revealed
a high correlation between mebendazole and other microtubule inhibitors.
Mebendazole, at both doses examined,
caused a significant extension of animal
survival: 33% increase in survival after
tumor cell implantation for mice treated
with 50 mg/kg of mebendazole and
43% increase with 100 mg/kg. We note
that these therapeutic effects are not as
robust as those obtained previously in
the same model (63% increase in survival for mice treated with 50 mg/kg
of mebendazole). A major factor that
likely contributes to the difference in
therapeutic efficacy is that in our study,
treatment was started much later (10 d)
after tumor cell implantation than in the
previous study (5 d) (24). In addition, the
GL261 cells used in our study appear to
be significantly more aggressive, as the
control mice survived for a significantly
shorter time, even though fewer tumor
cells were implanted.
Mebendazole is often said to be well
tolerated with few side effects (25,26).
However, at the higher doses and prolonged treatment periods necessary for
the clinical management of severe echinococcosis infection, and likely also for its
use as cancer chemotherapy, significant
toxicities have been observed, including
anemia, leukopenia and liver toxicity (27).
We also note that the treatment of mice
with both mebendazole and vincristine at
doses close to their respective MTDs rapidly led to severe toxicity, which cautions
against the combined use of these microtubule inhibitors in the clinic.
In contrast to mebendazole, we observed that vincristine, also at a dose
close to its MTD, failed to show any therapeutic benefit in the GL261-C57BL/6
model in the conditions that we used.
Most likely, this lack of efficacy is due to
vincristine’s poor BBB permeability (4,5),
in contrast to the good BBB permeability
of mebendazole (12).
The extensive use of vincristine in
brain tumor therapy (1–3) dates back
to a phase II study using a combination
of procarbazine, CCNU and vincristine

(PCV) to treat a wide range of brain
tumors (28). The introduction of this
combination was based on the therapeutic activity of procarbazine in an
intracerebral rat leukemia model (29)
and that of CCNU in orthotopic models
of glioma and ependymoblastoma (30).
Including vincristine in this regimen
was based on limited clinical experience in a small number of patients
(31,32).
CONCLUSION
Our findings documenting a lack of
therapeutic efficacy of vincristine in
a mouse model for glioma where mebendazole shows significant efficacy,
in addition to a lack of evidence for the
clinical benefit of vincristine in the treatment of brain tumors, strongly suggest
that vincristine should not be used chemotherapeutically in neuro-oncology.
Thus, as mebendazole and vincristine
have the same mechanism of action,
replacing vincristine with mebendazole
may facilitate the elimination of vincristine from neuro-oncological regimens.
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